PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Profitability reveals how effectively the business turns revenues into profits. Higher and improving margins or returns on capital suggest a durable competitive advantage, supporting a stronger intrinsic valuation.
0.74%
ROE near Drug Manufacturers - Specialty & Generic median of 0.74%. Charlie Munger would verify if similar industry forces drive comparable returns.
0.68%
ROA exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 0.31%. Mohnish Pabrai would see if this advantage is driven by brand or cost leadership.
0.36%
ROCE 75-90% of Drug Manufacturers - Specialty & Generic median of 0.47%. John Neff would want to see cost reductions or margin expansion.
78.85%
Gross margin 1.25-1.5x Drug Manufacturers - Specialty & Generic median of 56.08%. Mohnish Pabrai would verify if a unique value chain offers pricing benefits.
9.31%
Operating margin exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 4.16%. Joel Greenblatt would study if unique processes or brand lift margins.
18.09%
Net margin exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 3.28%. Joel Greenblatt would see if this advantage is sustainable across cycles.